SIOX insider filings

Sio Gene Therapies Inc. — 17 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2022-02-10. Screen SIOX transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for SIOX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Sio Gene Therapies Inc.

FiledFormInsiderReported transactionsSource
2022-02-104Meswani Parag V — Chief Commercial OfficerGrant/award (A): 153,700 (derivative) @ $0EDGAR
2022-02-104Nassif David W. — Interim CEO, CFO, DirectorGrant/award (A): 546,500 (derivative) @ $0EDGAR
2021-12-094Nassif David W. — Chief Financial OfficerGrant/award (A): 17,534 @ $0 · Tax withholding (F): 6,294 @ $1.42 · Disposition to issuer (D): 17,534 (derivative) @ $0EDGAR
2021-12-094Cheruvu Pavan — Chief Executive Officer, DirectorGrant/award (A): 37,567 @ $0 · Tax withholding (F): 14,884 @ $1.42 · Disposition to issuer (D): 37,567 (derivative) @ $0EDGAR
2021-04-194Torti Frank — DirectorGrant/award (A): 42,000 (derivative) @ $0EDGAR
2021-04-194Sundaram Senthil Vel — DirectorGrant/award (A): 42,000 (derivative) @ $0EDGAR
2021-04-194Pande Atul — DirectorGrant/award (A): 42,000 (derivative) @ $0EDGAR
2021-04-194Modig Berndt — DirectorGrant/award (A): 42,000 (derivative) @ $0EDGAR
2021-04-194Nassif David W. — Chief Financial OfficerGrant/award (A): 239,000 (derivative) @ $0EDGAR
2021-04-194Corcoran Gavin — Chief R&D OfficerGrant/award (A): 244,300 (derivative) @ $0EDGAR
2021-04-194Cheruvu Pavan — Chief Executive Officer, DirectorGrant/award (A): 682,100 (derivative) @ $0EDGAR
2021-04-194Vuori Kristiina MD — DirectorGrant/award (A): 42,000 (derivative) @ $0EDGAR
2021-03-244Cheruvu Pavan — Chief Executive Officer, DirectorPurchase (P): 100,000 @ $2.48EDGAR
2021-03-224Nassif David W. — Chief Financial OfficerGrant/award (A): 15,060 @ $0 · Disposition to issuer (D): 15,060 (derivative) @ $0EDGAR
2021-03-194Corcoran Gavin — Chief R&D OfficerGrant/award (A): 16,001 @ $0 · Disposition to issuer (D): 16,001 (derivative) @ $0EDGAR
2021-03-194Cheruvu Pavan — Chief Executive Officer, DirectorGrant/award (A): 22,590 @ $0 · Disposition to issuer (D): 22,590 (derivative) @ $0EDGAR
2020-11-254Pande Atul — DirectorPurchase (P): 10,000 @ $2.34EDGAR

Recent 8-K events — Sio Gene Therapies Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2023-04-068-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.07 — Submission of Matters to a Vote of Security Holders
EDGAR
2023-03-158-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2023-02-148-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2022-12-148-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2022-11-108-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2022-09-148-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2022-08-118-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2022-06-148-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2022-04-278-K1.02 — Termination of a Material Definitive Agreement
2.02 — Results of Operations and Financial Condition
?
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2022-03-188-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=SIOX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs